Full Press Release Details
Bio Announces Availability of Annual Report on Form 20-F Through Company Website
11, 2024- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases
that have significant unmet medical needs, today announced
that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2023, as filed
with the Securities and Exchange Commission on March 11, 2024, is available through its website (https://www.belitebio.com). Shareholders
may receive a hard copy of the annual report free of charge upon request. This press release is being issued pursuant to Nasdaq Listing
clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye
diseases which have significant unmet medical needs such as (i) atrophic age-related macular degeneration (AMD), commonly known as Geographic
Atrophy (GA) in advanced dry AMD, and (ii) autosomal recessive Stargardt disease type 1, or STGD1, in addition to specific metabolic